TP53 and cancer: For example, mutations in key survival pathways, such as the PI3K or p53 pathways, can confer cancer cells with different sensitivities to targeted therapy [11, 12], chemotherapy [13], and radiation [12], suggesting heterogeneity of cancer cells with these mutations could contribute to treatment resistance.